Universitatsklinikum Tulln
- Address
- lock Available on a paid plan
Universitätsklinikum Tulln - Neurological Disorders Center
Universitätsklinikum Tulln is a specialized medical research institution focused on advancing treatment options for complex neurological disorders. The center demonstrates particular expertise in investigating conditions affecting the autonomic nervous system and neurodegenerative diseases, with emphasis on improving quality of life for patients experiencing debilitating symptoms.
- Multiple System Atrophy (MSA) and related autonomic dysfunction
- Neurogenic Orthostatic Hypotension (nOH) symptom management
- Novel pharmacological interventions for autonomic nervous system disorders
The research team at Universitätsklinikum Tulln conducts comprehensive Phase 3 clinical trials evaluating both the efficacy and long-term durability of innovative therapeutics. Their rigorous study designs incorporate extended treatment periods and validated assessment tools such as the OHSA composite score, enabling thorough evaluation of treatment outcomes in patients with symptomatic neurogenic orthostatic hypotension associated with multiple system atrophy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universitatsklinikum Tulln
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Durability of Ampreloxetine in Treating Symptomatic Neurogenic Orthostatic Hypotension in Multiple System Atrophy: A Phase 3 Study | Theravance Biopharma Ireland Limited | Phase III | Not Recruiting | Oct 2023 | Jun 2026 |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ampreloxetine | 1 | Unknown | 2023-10-25 | 2023-10-25 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.